We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+51.05%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$154M
AUM Growth
-$23.7M
Cap. Flow
-$63.8M
Cap. Flow %
-41.47%
Top 10 Hldgs %
62.2%
Holding
45
New
6
Increased
7
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$9.41M
2
ELVN icon
Enliven Therapeutics
ELVN
+$4.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$1.63M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.48M
5
MREO
Mereo BioPharma
MREO
+$1.35M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$23.5M
2
KURA icon
Kura Oncology
KURA
+$11.9M
3
CBAY
Cymabay Therapeutics
CBAY
+$11.6M
4
EYPT icon
EyePoint Inc
EYPT
+$9.82M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
2 Financials 0.61%
3 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$2.23B
$24M 15.58%
2,635,287
+1,325,287
+101% +$9.41M
PRAX icon
2
Praxis Precision Medicines
PRAX
$8.67B
$9.9M 6.43%
162,302
-137,334
-46% -$6.16M
MRSN
3
DELISTED
Mersana Therapeutics
MRSN
$9.7M 6.3%
86,585
-8,135
-9% -$809K
TSHA icon
4
Taysha Gene Therapies
TSHA
$1.68B
$9.57M 6.21%
3,333,333
-256,000
-7% -$533K
RCKT icon
5
Rocket Pharmaceuticals
RCKT
$384M
$8.8M 5.72%
326,787
-39,228
-11% -$1.11M
SRPT icon
6
Sarepta Therapeutics
SRPT
$2.18B
$8.31M 5.4%
64,162
-6,438
-9% -$789K
PCVX icon
7
Vaxcyte
PCVX
$8.98B
$7.16M 4.65%
104,830
-12,543
-11% -$869K
ELVN icon
8
Enliven Therapeutics
ELVN
$3.68B
$6.97M 4.53%
396,099
+272,223
+220% +$4.18M
TRML
9
DELISTED
Tourmaline Bio
TRML
$5.98M 3.88%
261,108
+29,226
+13% +$1.03M
APLT
10
DELISTED
Applied Therapeutics
APLT
$5.39M 3.5%
792,000
+266,900
+51% +$1.2M
DYN icon
11
Dyne Therapeutics
DYN
$3.37B
$5.24M 3.4%
184,500
+36,664
+25% +$829K
IRON icon
12
Disc Medicine
IRON
$2.66B
$4.78M 3.11%
76,800
-38,700
-34% -$2.51M
RVMD icon
13
Revolution Medicines
RVMD
$42.2B
$4.63M 3.01%
143,777
-16,223
-10% -$481K
CLDX icon
14
Celldex Therapeutics
CLDX
$3.06B
$4.57M 2.97%
109,000
+39,600
+57% +$1.63M
WHWK
15
Whitehawk Therapeutics
WHWK
$233M
$4.33M 2.81%
1,849,402
– –
HLVX
16
DELISTED
HilleVax
HLVX
$4.17M 2.71%
250,609
-73,991
-23% -$1.18M
CRNX
17
DELISTED
Crinetics Pharmaceuticals
CRNX
$3.67M 2.38%
78,403
-9,097
-10% -$356K
VRDN icon
18
Viridian Therapeutics
VRDN
$2.48B
$3.49M 2.27%
199,433
-82,067
-29% -$1.59M
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$3.05M 1.98%
465,079
-90,181
-16% -$589K
IMVT icon
20
Immunovant
IMVT
$7.78B
$2.98M 1.94%
92,346
-27,143
-23% -$990K
VSTM icon
21
Verastem
VSTM
$684M
$2.44M 1.59%
207,095
-25,154
-11% -$291K
ACLX
22
DELISTED
Arcellx
ACLX
$2.4M 1.56%
34,500
-42,500
-55% -$2.7M
KURA icon
23
Kura Oncology
KURA
$1.04B
$1.92M 1.25%
90,000
-611,349
-87% -$11.9M
INSM icon
24
Insmed
INSM
$27.1B
$1.67M 1.09%
61,718
+32,218
+109% +$902K
AGIO icon
25
Agios Pharmaceuticals
AGIO
$2.01B
$1.62M 1.05%
+55,262
New +$1.48M
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Acuta Capital Partners held 45 positions worth $154M, down 13% from $178M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $63.8M in Q1 2024, closing 12 positions and reducing 17 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, Acuta Capital Partners opened a new position in Agios Pharmaceuticals worth $1.62M.

  • Acuta Capital Partners's largest Q1 2024 buy was Agios Pharmaceuticals: 55,262 shares worth $1.62M.
  • Acuta Capital Partners added most to Ocular Therapeutix in Q1 2024, an estimated $9.41M increase.
  • Acuta Capital Partners's biggest Q1 2024 reduction was Kura Oncology, cutting an estimated $11.9M.
  • Acuta Capital Partners fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $23.5M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $154M portfolio in Q1 2024.
  • Acuta Capital Partners opened 6 new positions and closed 12 in Q1 2024.
  • Acuta Capital Partners's portfolio value fell 13% quarter-over-quarter to $154M.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.